96 related articles for article (PubMed ID: 30480474)
1. BIM deletion polymorphism accounts for lack of favorable outcome in Japanese females with follicular lymphoma.
Ito Y; Umezu T; Tadokoro K; Saito Y; Katagiri S; Suguro T; Asano M; Yoshizawa S; Akahane D; Tanaka Y; Fujimoto H; Okabe S; Gotoh M; Tauchi T; Kawana C; Ohyashiki JH; Nakamura N; Ohyashiki K
Leuk Lymphoma; 2019 May; 60(5):1283-1288. PubMed ID: 30480474
[TBL] [Abstract][Full Text] [Related]
2. BCL2-like 11 intron 2 deletion polymorphism is not associated with non-small cell lung cancer risk and prognosis.
Cho EN; Kim EY; Jung JY; Kim A; Oh IJ; Kim YC; Chang YS
Lung Cancer; 2015 Oct; 90(1):106-10. PubMed ID: 26271547
[TBL] [Abstract][Full Text] [Related]
3. The genotype of MLH1 identifies a subgroup of follicular lymphoma patients who do not benefit from doxorubicin: FIL-FOLL study.
Rossi D; Bruscaggin A; La Cava P; Galimberti S; Ciabatti E; Luminari S; Rigacci L; Tucci A; Pulsoni A; Bertoldero G; Vallisa D; Rusconi C; Spina M; Arcaini L; Angrilli F; Stelitano C; Merli F; Gaidano G; Federico M; Palumbo GA
Haematologica; 2015 Apr; 100(4):517-24. PubMed ID: 25596266
[TBL] [Abstract][Full Text] [Related]
4. Clinical Implications of the BIM Deletion Polymorphism in Advanced Lung Adenocarcinoma Treated With Gefitinib.
Yuan J; Li B; Zhang N; Zhu H; Zhou L; Zhang L; Yang M
Clin Lung Cancer; 2018 Jul; 19(4):e431-e438. PubMed ID: 29580739
[TBL] [Abstract][Full Text] [Related]
5. EGFR-TKIs plus chemotherapy demonstrated superior efficacy than EGFR-TKIs alone as first-line setting in advanced NSCLC patients with EGFR mutation and BIM deletion polymorphism.
Liu S; He Y; Jiang T; Ren S; Zhou F; Zhao C; Li X; Zhang J; Su C; Chen X; Cai W; Gao G; Li W; Wu F; Li J; Zhao J; Hu Q; Zhao M; Zhou C; Hirsch FR
Lung Cancer; 2018 Jun; 120():82-87. PubMed ID: 29748021
[TBL] [Abstract][Full Text] [Related]
6. Bcl-2-like protein 11 deletion polymorphism predicts survival in advanced non-small-cell lung cancer.
Lee JH; Lin YL; Hsu WH; Chen HY; Chang YC; Yu CJ; Shih JY; Lin CC; Chen KY; Ho CC; Laio WY; Yang PC; Yang JC
J Thorac Oncol; 2014 Sep; 9(9):1385-92. PubMed ID: 25057939
[TBL] [Abstract][Full Text] [Related]
7. Prespecified candidate biomarkers identify follicular lymphoma patients who achieved longer progression-free survival with bortezomib-rituximab versus rituximab.
Coiffier B; Li W; Henitz ED; Karkera JD; Favis R; Gaffney D; Shapiro A; Theocharous P; Elsayed YA; van de Velde H; Schaffer ME; Osmanov EA; Hong X; Scheliga A; Mayer J; Offner F; Rule S; Teixeira A; Romejko-Jarosinska J; de Vos S; Crump M; Shpilberg O; Zinzani PL; Cakana A; Esseltine DL; Mulligan G; Ricci D
Clin Cancer Res; 2013 May; 19(9):2551-61. PubMed ID: 23549871
[TBL] [Abstract][Full Text] [Related]
8. Inactivation of the CDKN2A tumor-suppressor gene by deletion or methylation is common at diagnosis in follicular lymphoma and associated with poor clinical outcome.
Alhejaily A; Day AG; Feilotter HE; Baetz T; Lebrun DP
Clin Cancer Res; 2014 Mar; 20(6):1676-86. PubMed ID: 24449825
[TBL] [Abstract][Full Text] [Related]
9. High Prevalence of the BIM Deletion Polymorphism in Young Female Breast Cancer in an East Asian Country.
Lin CH; Shen CY; Lee JH; Huang CS; Yang CH; Kuo WH; Chang DY; Hsiung CN; Kuo KT; Chen WW; Chen IC; Wu PF; Kuo SH; Chen CJ; Lu YS; Cheng AL
PLoS One; 2015; 10(4):e0124908. PubMed ID: 25909194
[TBL] [Abstract][Full Text] [Related]
10. Association between BIM polymorphism and lung cancer outcomes: a meta-analysis.
Li XF; Wu LX; Chen HF; Zhu YC; Wang WX; Xu CW; Lin XP; Xie DF; Du KQ
Cell Mol Biol (Noisy-le-grand); 2018 Aug; 64(11):92-96. PubMed ID: 30213299
[TBL] [Abstract][Full Text] [Related]
11. Treatment outcomes and clinical relevance of the Follicular Lymphoma International Prognostic Index in Korean follicular lymphoma patients treated with chemotherapy.
Maeng CH; Ahn SW; Ryu SY; Han S; Ko YH; Ji JH; Kim WS; Kim SJ
Korean J Intern Med; 2016 May; 31(3):560-9. PubMed ID: 26898595
[TBL] [Abstract][Full Text] [Related]
12. BIM deletion polymorphism profiling complements prognostic values of risk scores in imatinib-treated Asian chronic myeloid leukemia patients.
Than H; Lye WK; Sng C; Allen JC; Ong ST; Chuah C
Leuk Lymphoma; 2019 Jan; 60(1):234-237. PubMed ID: 29916288
[No Abstract] [Full Text] [Related]
13. A systematic review and meta-analysis of individual patient data on the impact of the BIM deletion polymorphism on treatment outcomes in epidermal growth factor receptor mutant lung cancer.
Soh SX; Siddiqui FJ; Allen JC; Kim GW; Lee JC; Yatabe Y; Soda M; Mano H; Soo RA; Chin TM; Ebi H; Yano S; Matsuo K; Niu X; Lu S; Isobe K; Lee JH; Yang JC; Zhao M; Zhou C; Lee JK; Lee SH; Lee JY; Ahn MJ; Tan TJ; Tan DS; Tan EH; Ong ST; Lim WT
Oncotarget; 2017 Jun; 8(25):41474-41486. PubMed ID: 28467813
[TBL] [Abstract][Full Text] [Related]
14. Role of BIM Deletion Polymorphism and BIM Expression as Predictive Biomarkers to Maximize the Benefit of EGFR-TKI Treatment in EGFR-Positive NSCLC.
Incharoen P; Charonpongsuntorn C; Saowapa S; Sirachainan E; Dejthevaporn T; Kampreasart K; Trachu N; Muntham D; Reungwetwattana T
Asian Pac J Cancer Prev; 2019 Dec; 20(12):3581-3589. PubMed ID: 31870097
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors and a predictive model of follicular lymphoma: a 25-year study at a single institution in Japan.
Katsumata N; Matsuno Y; Nakayama H; Takenaka T; Kobayashi Y; Takeyama K; Narabayashi M; Fukushima T; Yokozawa T; Nakata M; Tajima K; Ikeda H; Tobinai K
Jpn J Clin Oncol; 1996 Dec; 26(6):445-54. PubMed ID: 9001350
[TBL] [Abstract][Full Text] [Related]
16. Association of BIM Deletion Polymorphism and BIM-γ RNA Expression in NSCLC with EGFR Mutation.
Isobe K; Kakimoto A; Mikami T; Kaburaki K; Kobayashi H; Yoshizawa T; Makino T; Otsuka H; Sano GO; Sugino K; Sakamoto S; Takai Y; Tochigi N; Iyoda A; Homma S
Cancer Genomics Proteomics; 2016 11-12; 13(6):475-482. PubMed ID: 27807070
[TBL] [Abstract][Full Text] [Related]
17. Association of VEGFA-2578 C>A polymorphism with clinicopathological aspects and outcome in follicular lymphoma patients.
de Mendonça GR; Brito AB; Rocha RM; Delamain MT; de Andrade Natal R; Soares FA; Colleoni GW; Souza CA; Vassallo J; Lima CS
Blood Cancer J; 2016 Aug; 6(8):e464. PubMed ID: 27564462
[No Abstract] [Full Text] [Related]
18. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database.
Procházka V; Papajík T; Janíková A; Belada D; Kozák T; Šálek D; Sýkorová A; Móciková H; Campr V; Dlouhá J; Langová K; Fürst T; Trněný M
Leuk Lymphoma; 2017 Mar; 58(3):601-613. PubMed ID: 27666539
[TBL] [Abstract][Full Text] [Related]
19. FcgammaRIIIA and FcgammaRIIA polymorphisms do not predict clinical outcome of follicular non-Hodgkin's lymphoma patients treated with sequential CHOP and rituximab.
Carlotti E; Palumbo GA; Oldani E; Tibullo D; Salmoiraghi S; Rossi A; Golay J; Pulsoni A; Foà R; Rambaldi A
Haematologica; 2007 Aug; 92(8):1127-30. PubMed ID: 17650444
[TBL] [Abstract][Full Text] [Related]
20. Prognostic value of the soluble interleukin-2 receptor level after patients with follicular lymphoma achieve a response to R-CHOP.
Umino K; Fujiwara SI; Ikeda T; Toda Y; Ito S; Mashima K; Minakata D; Nakano H; Yamasaki R; Kawasaki Y; Sugimoto M; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Hematology; 2017 Oct; 22(9):521-526. PubMed ID: 28413914
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
